Jon Ruckle, M.D., CPI, principal at Pacific Pharma Group, will collaborate with DCR to continue to expand DCR’s Phase I research capabilities. Dr. Ruckle has served as investigator for more than 350 studies across multiple therapeutic areas including diabetes, cardiovascular disease, hypertension and osteoporosis, as well as first-in-human trials with biologics and small molecules.
“We are excited to enter into this consulting relationship with Pacific Pharma Group and to extend our scientific team to include the experience of Dr. Ruckle,” said Chad Jaeger, vice president of early clinical research at DCR. “Our intense focus on patient safety and scientific integrity in complex clinical pharmacology services aligns well with this collaboration and the needs of our customers.”
“State-of-the-art, hospital-based Phase I facilities offering access to both patient and healthy normal populations are of great interest to pharmaceutical researchers,” said Dr. Ruckle. “Through our relationship with DCR, Pacific Pharma Group will be able to offer clients access to these valuable services.”